Vanda president and CEO Mihael Polymeropoulos said: "The MAA validation demonstrates Vanda’s commitment to offer another option to the healthcare community to treat a severe, disabling mental disorder.
"This continues our efforts to expand the availability of iloperidone to people who we believe would benefit from this treatment option."
The MAA is primarily supported by data from two placebo- and active-controlled clinical trials and one long term randomized clinical trial. Fanaptum was shown to be superior to placebo in controlling symptoms of schizophrenia.
Iloperidone is currently approved in the U.S. as Fanapt for the treatment of schizophrenia in adults. Fanapt is also approved and marketed in Israel and Mexico.